Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (512) : Unable to emit headers. Headers sent in file=/home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php line=36 [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 71]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 168]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 197]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 236]
Ikena Oncology, Inc. - Market capitalization
companies: 6,640     total market cap: $100.86 T
Ikena Oncology, Inc.
IKNA

$82.04 M
Marketcap
$1.70
Share price
US
Country
N/A
Change (1 day)
N/A
Year High
N/A
Year Low
Biotechnology
Categories

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

marketcap

P/S ratio for Ikena Oncology, Inc. (IKNA)

P/S ratio as of 2023: 8.98

According to Ikena Oncology, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.98. At the end of 2022 the company had a P/S ratio of 6.16.

P/S ratio history for Ikena Oncology, Inc. from 2018 to 2023

P/S ratio at the end of each year

Year P/S ratio
2023 8.98
2022 6.16
2021 14.56
2020 124.78
2019 83.42
2018 1158.83

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company. In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

Stock prices are delayed, the delay can range from a few minutes to several hours. MarketCap.tools is not a Financial institution.

Contact

For inquiries or if you want to report a problem write to web@marketcap.tools

© 2023 Marketcap.tools